Skip to main content
. 2022 Aug 12;3(10):1720–1729. doi: 10.34067/KID.0000352022

Table 2.

Baseline demographics of study patients

Characteristic Control (n=16) Intervention (n=19)
Age (yr), mean (SD) 68 (14) 69 (11)
Sex, n (%)
 Female 8 (50) 11 (58)
 Male 8 (50) 8 (42)
Race, n (%)
 American Indian or Alaska Native 0 (0.0) 1 (5)
 Asian 0 (0.0) 1 (5)
 Black or African American 6 (38) 4 (21)
 White 10 (63) 13 (68)
Ethnicity, n (%)
 Hispanic/Latino 0 (0) 3 (16)
 Non-Hispanic or Latino 16 (100) 16 (84)
Education, n (%)
 Less than high school 1 (7) 0 (0)
 High school/GED 3 (21) 9 (47)
 College 5 (36) 4 (21)
 Graduate/professional degree 5 (36) 6 (32)
Comorbidities, n (%)
 Cancer (history of or in remission) 3 (19) 1 (5)
 Congestive heart failure 1 (6) 0 (0)
 Coronary artery disease 3 (19) 2 (11)
 Diabetes 5 (31) 10 (53)
 Liver disease 1 (6) 0 (0)
 None of the above 0 (0) 3 (16)
 Other 3 (19) 3 (16)
Charlson Comorbidity Index, mean (SD) 6 (2) 5 (2)
Karnofsky Performance Score, mean (SD) 66 (26) 78 (19)
GFR (ml/min per 1.73 m2), mean (SD) 11 (2) 11 (5)
Cause of kidney failure, n (%)
 Diabetes 4 (25) 4 (21)
 Glomerular disease 2 (13) 0 (0)
 Hypertension 5 (31) 10 (53)
 Other 5 (31) 5 (26)
Albumin (g/dl), mean (SD) 3.8 (0.40) 3.9 (0.4)
Hemoglobin (g/dl), mean (SD) 9.5 (1.90) 10.0 (1.6)
Lives alone, n (%) 7 (50) 8 (42)
Presence of a health care proxy, n (%) 11 (79) 11 (58)
Presence of advance care planning documents, n (%) 5 (36) 4 (21)

GED, General Education Development Test.